NCT02658214 - Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2016

Primary Completion Date

November 14, 2019

Study Completion Date

November 14, 2019

Conditions

Small Cell Lung CarcinomaCarcinoma, Squamous Cell of Head and NeckStomach NeoplasmsTriple Negative Breast NeoplasmsOvarian NeoplasmsFallopian Tube NeoplasmsPeritoneal NeoplasmsEsophagogastric Junction NeoplasmsCarcinoma, Pancreatic DuctalEsophageal Squamous Cell Carcinoma

Interventions

DRUG

paclitaxel + carboplatin

IV infusion

DRUG

carboplatin + etoposide

IV infusion

DRUG

gemcitabine + carboplatin

IV infusion

DRUG

nab-paclitaxel (paclitaxel-albumin) + carboplatin

IV infusion

DRUG

oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)

IV infusion and bolus administration

BIOLOGICAL

durvalumab

IV infusion

BIOLOGICAL

tremelimumab

IV infusion

DRUG

nab-paclitaxel (paclitaxel-albumin) + gemcitabine

IV infusion

DRUG

cisplatin + 5-fluorouracil (5FU)

IV infusion

Trial Locations (6)

104-0045

Research Site, Chūōku

277-8577

Research Site, Kashiwa

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

135-710

Research Site, Seoul